Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Mirdametinib in Participants With Hepatic Impairment
NCT06997276Phase 1Recruiting
- Sponsor
- SpringWorks Therapeutics
- Start
- Apr 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mirdametinib (3 arms), sponsored by SpringWorks Therapeutics. Primary endpoints: Maximum plasma concentration of mirdametinib, Time of maximum observed concentration of mirdametinib and 2 more. Started Apr 2025; status: recruiting.
02
Drugs
mirdametinib
Beyond the preview
Go deeper on NCT06997276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06997276.